Unknown

Dataset Information

0

Evolutionary Pressure against MHC Class II Binding Cancer Mutations.


ABSTRACT: The anti-cancer immune response against mutated peptides of potential immunological relevance (neoantigens) is primarily attributed to MHC-I-restricted cytotoxic CD8+ T cell responses. MHC-II-restricted CD4+ T cells also drive anti-tumor responses, but their relation to neoantigen selection and tumor evolution has not been systematically studied. Modeling the potential of an individual's MHC-II genotype to present 1,018 driver mutations in 5,942 tumors, we demonstrate that the MHC-II genotype constrains the mutational landscape during tumorigenesis in a manner complementary to MHC-I. Mutations poorly bound to MHC-II are positively selected during tumorigenesis, even more than mutations poorly bound to MHC-I. This emphasizes the importance of CD4+ T cells in anti-tumor immunity. In addition, we observed less inter-patient variation in mutation presentation for MHC-II than for MHC-I. These differences were reflected by age at diagnosis, which was correlated with presentation by MHC-I only. Collectively, our results emphasize the central role of MHC-II presentation in tumor evolution.

SUBMITTER: Marty Pyke R 

PROVIDER: S-EPMC6482006 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5711564 | BioStudies
2016-01-01 | S-EPMC5341866 | BioStudies
2014-01-01 | S-EPMC4004114 | BioStudies
2016-01-01 | S-EPMC5173042 | BioStudies
2016-01-01 | S-EPMC4683358 | BioStudies
2008-01-01 | S-EPMC2810506 | BioStudies
2018-01-01 | S-EPMC6220790 | BioStudies
2020-01-01 | S-EPMC7479950 | BioStudies
2016-01-01 | S-EPMC4740184 | BioStudies
2020-01-01 | S-EPMC7065958 | BioStudies